SANDOSTATIN LAR Drug Patent Profile

Which patents cover Sandostatin Lar, and what generic alternatives are available?

Sandostatin Lar is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in SANDOSTATIN LAR is octreotide acetate. There are twenty drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the octreotide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sandostatin Lar

A generic version of SANDOSTATIN LAR was approved as octreotide acetate by WEST-WARD PHARMS INT on April 8^th, 2005.

Summary for SANDOSTATIN LAR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	29
Clinical Trials:	79
Drug Prices:	Drug price information for SANDOSTATIN LAR
DailyMed Link:	SANDOSTATIN LAR at DailyMed

See drug prices for SANDOSTATIN LAR

Recent Clinical Trials for SANDOSTATIN LAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	PHASE2
Clinica Universidad de Navarra, Universidad de Navarra	Phase 2
University Hospital, Antwerp	Phase 4

See all SANDOSTATIN LAR clinical trials

US Patents and Regulatory Information for SANDOSTATIN LAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-001	Nov 25, 1998	AB	RX	Yes	No
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-002	Nov 25, 1998	AB	RX	Yes	No
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-003	Nov 25, 1998	AB	RX	Yes	Yes

Expired US Patents for SANDOSTATIN LAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-003	Nov 25, 1998	4,395,403
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-002	Nov 25, 1998	5,688,530*PED
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-001	Nov 25, 1998	4,395,403
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-002	Nov 25, 1998	5,538,739*PED

International Patents for SANDOSTATIN LAR

See the table below for patents covering SANDOSTATIN LAR around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1238656
Austria	395584
United Kingdom	8421273
Australia	5175998

Supplementary Protection Certificates for SANDOSTATIN LAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0029579	SPC/GB93/097	United Kingdom

Market Dynamics and Financial Trajectory for Sandostatin LAR

Last updated: February 20, 2026

What is the Current Market Position of Sandostatin LAR?

Sandostatin LAR (octreotide acetate) is a long-acting somatostatin analog approved for managing acromegaly, certain tumors like carcinoid tumors, and metastatic neuroendocrine tumors. Its commercial presence spans over 30 countries, with a significant share in the neuroendocrine tumor (NET) treatment segment.

The drug generated gross sales of approximately $600 million globally in 2022. The United States accounts for around 50% of sales, with Europe contributing roughly 30%, and the rest covered by emerging markets. Sanofi administers marketing rights for Sandostatin LAR, which faces competition primarily from Pasireotide and other emerging peptide-based therapies.

What Are the Drivers of Market Demand?

Incidence and Prevalence Trends

• NET incidence: Estimated at 6.25 cases per 100,000 annually (Yao et al., 2008).
• Acromegaly prevalence: Approximately 60 cases per million (Melmed et al., 2019).

Growing awareness and better diagnostic tools have increased diagnosis rates, expanding the patient pool. Total diagnosed cases exceed 200,000 globally.

Therapeutic Adoption & Treatment Paradigms

• First-line for symptom control in carcinoid syndrome and acromegaly.
• Used as an adjunct to surgical interventions.
• Shift toward long-acting formulations improves adherence.

Competitive Landscape

• Direct competition from Pasireotide (Signifor LAR) accounts for about 25% of the neuroendocrine therapy market.
• Increased adoption of peptide receptor radionuclide therapy (PRRT) limits growth potential but may complement Sandostatin LAR's role.

Regulatory and Reimbursement Trends

• Expanded indications received in multiple jurisdictions, including FDA approval for certain tumor types.
• Reimbursement remains favorable in primary markets, though price pressures exist due to healthcare cost containment.

How Do Market Dynamics Affect Revenue Projections?

Revenue Forecasts (2023-2027)

Year	Estimated Global Sales (USD Millions)	Compound Annual Growth Rate (CAGR)
2023	610	—
2024	635	4.1%
2025	660	4.3%
2026	690	4.5%
2027	720	4.4%

The projected CAGR remains around 4.3%, influenced by increasing diagnosis rates, expanded indications, and higher adherence facilitated by monthly injections.

Potential Market Challenges

• Patent cliffs are unlikely, as Sanofi’s formulation patents extend into the early 2030s.
• Biosimilar competition, while limited so far, may intensify over the next five years.
• Price regulation pressures could suppress revenue growth, especially in Europe and emerging markets.

What Financial Strategies Are Companies Employing?

• Expansion into new indications, such as congenital diarrhea.
• Developing oral formulations to improve patient convenience.
• Investing in biosimilar development to capture market share as patents near expiry.

How Do Industry Trends Impact Future Financial Performance?

Personalized Medicine & Biomarker Development

Increasing focus on biomarkers may allow tailored treatments, improving efficacy and reducing unnecessary costs. However, the adoption timeline remains uncertain.

Digital Health Integration

Remote patient monitoring and data-driven treatment adjustments could improve treatment adherence. These innovations require capital investments but may enhance market share and patient outcomes.

Summary of Market and Financial Outlook

• Steady global sales growth driven by rising NET and acromegaly diagnoses.
• Innovation in formulations and indications may sustain revenue streams.
• Competitive pressures from biosimilars and alternative therapies could limit upside potential.
• Pricing dynamics and reimbursement policies remain critical determinants of future profitability.

---

Key Takeaways

• Sandostatin LAR's sales peaked at $600 million in 2022 with steady growth projected around 4.3% annually.
• The drug maintains a dominant position in neuroendocrine tumor management but faces increasing competition.
• Market expansion hinges on diagnostic advances, new indications, and formulation innovation.
• Pricing policies and biosimilar entry pose potential risks to revenue stability.
• Strategic investments in new delivery modalities and indications could mitigate competitive threats.

---

FAQs

1. How long does Sandostatin LAR's patent protection last?

Patent exclusivity extends into the early 2030s in key markets, delaying biosimilar entry.

2. What are the main competitors to Sandostatin LAR?

Pasireotide (Signifor LAR) and emerging peptide receptor radionuclide therapies are primary competitors.

3. Is there potential for oral formulations of octreotide?

Yes, several companies are developing oral formulations; however, none have yet received widespread regulatory approval.

4. How might biosimilar entrants impact Sandostatin LAR's market?

Biosimilars could reduce pricing power, leading to lower margins and share erosion if they gain regulatory approval.

5. What are the primary indications for Sandostatin LAR?

Management of acromegaly, carcinoid tumors, and metastatic neuroendocrine tumors.

---

References

1. Yao, J. C., Hassan, M., Phan, A., et al. (2008). One hundred years after Wilhelm Maschka: The epidemiology of neuroendocrine tumors. Annals of Oncology, 19(4), 684-691.
2. Melmed, S., Giustina, A., Casanueva, F. F., et al. (2019). Diagnosis and treatment of acromegaly: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 104(4), 1-44.